Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.

Autor: D'Cunha R; Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA., Azam T; Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA., Kalabic J; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany., Anschutz T; Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA., Lahat A; Chaim Sheba Medical Center, Tel Aviv University, Ramat Aviv, 69978, Tel Aviv, Israel.; Samson Assuta Ashdod Medical Center, Affiliated with Ben Gurion University of the Negev, Be'er Sheva, Israel., Pang Y; Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA. yinuo.pang@abbvie.com.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Dec 21. Date of Electronic Publication: 2024 Dec 21.

Correction to "The Localized Active Space Method with Unitary Selective Coupled Cluster".

Autor: Mitra A, D'Cunha R, Wang Q, Hermes MR, Alexeev Y, Gray SK, Otten M, Gagliardi L

Publikováno v: Journal of chemical theory and computation [J Chem Theory Comput] 2025 Jan 02. Date of Electronic Publication: 2025 Jan 02.

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.

Autor: Louis E; Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium., Schreiber S; Department of Internal Medicine, University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel, Kiel, Germany., Panaccione R; Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada., Bossuyt P; Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium., Biedermann L; Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland., Colombel JF; Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Parkes G; Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, England., Peyrin-Biroulet L; Department of Gastroenterology and INSERM U1256, University Hospital of Nancy, Lorraine University, Vandoeuvre, France., D'Haens G; Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Hisamatsu T; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan., Siegmund B; Department of Gastroenterology, Infectiology and Rheumatology, Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Wu K; State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China., Boland BS; Division of Gastroenterology, University of California-San Diego, La Jolla., Melmed GY; F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, California., Armuzzi A; IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Levine P; AbbVie Inc, North Chicago, Illinois., Kalabic J; AbbVie Deutschland GmbH and Co KG, Ludwigshafen, Germany., Chen S; AbbVie Inc, North Chicago, Illinois., Cheng L; AbbVie Inc, North Chicago, Illinois., Shu L; AbbVie Inc, North Chicago, Illinois., Duan WR; AbbVie Inc, North Chicago, Illinois., Pivorunas V; AbbVie Inc, North Chicago, Illinois., Sanchez Gonzalez Y; AbbVie Inc, North Chicago, Illinois., D'Cunha R; AbbVie Inc, North Chicago, Illinois., Neimark E; AbbVie Inc, North Chicago, Illinois., Wallace K; AbbVie Inc, North Chicago, Illinois., Atreya R; First Department of Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany., Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.

Publikováno v: JAMA [JAMA] 2024 Sep 17; Vol. 332 (11), pp. 881-897.

A first-in-human study of the novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants.

Autor: D'Cunha R; AbbVie, North Chicago, Illinois, USA., Kupper H; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany., Arikan D; AbbVie, North Chicago, Illinois, USA., Zhao W; AbbVie, North Chicago, Illinois, USA., Carter D; AbbVie, North Chicago, Illinois, USA., Blaes J; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany., Ruzek M; AbbVie Bioresearch Center, Worcester, Massachusetts, USA., Pang Y; AbbVie, North Chicago, Illinois, USA.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Jan; Vol. 90 (1), pp. 189-199. Date of Electronic Publication: 2023 Sep 04.

Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.

Autor: Buttgereit F; Department of Rheumatology and Clinical Immunology, Charité University Medicine, and Clinical Immunology, Berlin, Germany., Aelion J; West Tennessee Research Institute, Jackson, Tennessee., Rojkovich B; Polyclicic of the Hospitaller Brothers of St. John of God in Budapest, Budapest, Hungary., Zubrzycka-Sienkiewicz A; Reumatika-Centrum Reumatologii, ARS Rheumatica sp.z.o.o, Warsaw, Poland., Chen S; AbbVie Inc., North Chicago, Illinois., Yang Y; AbbVie Inc., North Chicago, Illinois., Arikan D; AbbVie Inc., North Chicago, Illinois., D'Cunha R; AbbVie Inc., North Chicago, Illinois., Pang Y; AbbVie Inc., North Chicago, Illinois., Kupper H; AbbVie Deutschland GmbH & Co., KG, Ludwigshafen, Germany., Radstake T; AbbVie Inc., North Chicago, Illinois., Amital H; Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases Medical Center, Department of Medicine 'B', Tel-Hashomer, Israel, and the Sheba Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Publikováno v: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2023 Jun; Vol. 75 (6), pp. 879-889. Date of Electronic Publication: 2023 Apr 02.